IDBI Healthcare Fund - Growth - Direct Plan

  • Previous Nav

  • Net Change on 22-10-2021

  • PersonalFN Rating

  • Assets (Cr.)

  • Expense Ratio

Fund Overview Growth | Direct Plan

  • Fund House

  • Launch Date

  • Benchmark

  • Minimum Investment (₹)

  • Minimum Addl Investment (₹)

  • Exit Load (%)

  • Minimum SIP Investment (₹)

  • Minimum STP Investment (₹)

  • Minimum SWP Investment (₹)

  • 52 Week Low Nav (₹)

  • 52 Week Low Nav Date

  • 52 Week High Nav (₹)

  • 52 Week High Nav Date

Fund Objective

The objective of the Scheme is to achieve long term capital appreciation by predominantly investing in equity and equity related instruments of companies engaged in Healthcare and Allied sectors. However there can be no assurance that the investment objective under the scheme will be realized.

Fund Performance

Scheme Name 1-Month Return (%) 3-Month Return (%) 1-Year Return (%) 3-Year Return (%) 5-Year Return (%) Since Inception
NIFTY 50 - TRI N/A N/A N/A N/A N/A N/A
S&P BSE Health Care - TRI -5.01 -4.52 28.20 20.77 9.63 15.28

Returns upto 1 year is Absolute, and above 1 year are Compounded Annualised

Peer Fund Comparison

Scheme Name Launch Date Ratings 1-Year Return (%) 3-Year Return (%) 5-Year Return (%) Expense Ratio (%) Assets (Cr.)
Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option - Growth Jan 01, 2013 34.22 26.03 16.38 0.90 5,474.07
SBI HEALTHCARE OPPORTUNITIES FUND - DIRECT PLAN -GROWTH Jan 01, 2013 27.30 23.81 10.41 1.07 2,001.26
UTI Healthcare Fund - Direct Plan - Growth Option Jan 01, 2013 28.18 25.39 12.78 1.24 879.57
Tata India Pharma & Healthcare Fund-Direct Plan-Growth Dec 28, 2015 29.55 27.04 14.37 1.06 590.03

Fund Holdings as on 30-September-2021

  • Sun Pharmaceutical Industries Ltd.

  • Divi's Laboratories Ltd.

  • Dr. Reddy's Laboratories Ltd.

  • Cipla Ltd.

  • Apollo Hospitals Enterprise Ltd.

  • Aurobindo Pharma Ltd.

  • Lupin Ltd.

  • IPCA Laboratories Ltd.

  • JB Chemicals & Pharmaceuticals Ltd.

  • Alkem Laboratories Ltd.

  • Gland Pharma Ltd.

  • Abbott India Ltd.

  • Torrent Pharmaceuticals Ltd.

  • Laurus Labs Ltd.

  • Jubilant Ingrevia Ltd.

  • Net Receivable / Payable

  • Syngene International Ltd.

  • Rossari Biotech Ltd.

  • Pfizer Ltd.

  • Cadila Healthcare Ltd.

  • Tata Steel Ltd.

  • Vinati Organics Ltd.

  • Biocon Ltd.

  • Aster DM Healthcare Ltd.

  • ICICI Lombard General Insurance Company Ltd.

  • Metropolis Healthcare Ltd.

  • HDFC Life Insurance Company Ltd.

  • Indoco Remedies Ltd.

  • Natco Pharma Ltd.

  • Strides Pharma Science Ltd.

  • TREPS

  • AstraZeneca Pharma India Ltd.

View More
  • Pharmaceuticals & Drugs

  • Hospital & Healthcare Services

  • Chemicals

  • Miscellaneous

  • Insurance

  • Steel & Iron Products

View More

About IDBI Healthcare Fund

Scheme Analysis

IDBI Healthcare Fund is a Equity - Sectoral Fund - Pharma & Health Care fund and belongs to IDBI Mutual Fund. It was launched on 28-Feb-2019 and currently has an AUM of ₹79.95 crore. IDBI Healthcare Fund is benchmarked against NIFTY 50 - TRI as primary index and S&P BSE Health Care - TRI as secondary index.

The NAV of IDBI Healthcare Fund ended down ₹-0.29(-1.45%)yesterday to ₹19.76.

Among its top 3 holdings the fund has exposure to Sun Pharmaceutical Industries Ltd., and

The IDBI Healthcare Fund is managed by Alok Ranjan .

Fund House Contact

5th floor, Mafatlal Centre, Nariman Point Mumbai - 400021

022-6644 2800
022-6644 2802